



# Communique

<b>Security</b>	Public
<b>Distribution</b>	Widespread distribution - metropolitan, regional, public
<b>Target audience</b>	All stakeholders

**Incident Name:** Targeted Regional WA MenW Outbreak Response

**Communique. 12** (covers period 5.1.2018-12.1.2018). **New information in bold, blue font.**

**Day, date and time:** Friday, 12 January 2018

**This communique has been authorised by:** Dr Paul Effler

## Background

- Invasive meningococcal disease (IMD) due to meningococcal serogroup W (MenW) has risen rapidly across Australia since 2014.
- A statewide MenACWY vaccination program for 15-19 year olds commenced in April 2017.
- An outbreak of MenW in central Australia started in July 2017. Aboriginal people living in communities across a broad area in the Central Australia, Barkly, and Katherine regions of the Northern Territory (NT) and the Anangu Pitjantjatjara Yankunytjatjara (APY) Lands of South Australia (SA) have been affected. There have been four related cases reported in WA and two in Queensland.
- Meningococcal ACWY (MenACWY) vaccination programs have been introduced in NT, the APY Lands of SA, WA and Queensland in response to this outbreak.
- In Stage 1 of WA’s response, free MenACWY vaccination is being offered to all people aged 2 months and over living in Aboriginal communities that have strong cultural links with central Australian communities affected by the outbreak, i.e. the Ngaanyatjarra Lands and Tjuntjuntjara (Goldfields); Balgo, Bililuna, Kundat Jaru (Ringer Soak) and Mulan (Kimberley); and Punmu, Kunawarritji, Parnngurr (Cotton Creek), and Jigalong (Pilbara). The estimated target population in Stage 1 is 3,300 people and will extend from 18 October to 17 December.
- In accordance with the *Emergency Response Plan for Communicable Disease Incidents of National Significance* (CDPlan), on 2 November 2017, the Australian Chief Medical Officer declared the MenW outbreak in Indigenous people in remote Central Australian communities and other communities linked through culture and mobility a ‘Communicable Disease Incident of National Significance’ (CDINS).
- Following a case of MenW in an Aboriginal infant from the Goldfields in late November 2017, which brought to four the number of MenW cases in the Goldfields in 2017, ‘Stage 2’ of the targeted vaccination program has seen it expand to several additional towns and Aboriginal communities in the Goldfields and Midwest. In addition to the 3,500 people targeted in Stage 1, around 3,700 people are being targeted in Stage 2, which started on 28 November 2017 and will continue until 28 February 2018.

## Current situation

### Cases linked to the central Australia outbreak (NT, SA, WA, Qld)

- **Total number of cases: 35**
- **Total number of deaths: 1**

WA cases linked to the central Australia outbreak

- Total number of cases: 5, one case in an Aboriginal child in Kalgoorlie in early January
- Total number of deaths: 1

#### Other:

- Stage 1 of the vaccination program was completed on 17.12.2107 and achieved 96% coverage of the targeted population. Stage 2 has achieved **84%** coverage of the targeted population in the Midwest and **56%** in the Goldfields.
- **Clinician advice, FAQs and other resources have been updated and can be found at [http://ww2.health.wa.gov.au/Articles/N\\_R/Remote-WA-free-meningococcal-vaccine](http://ww2.health.wa.gov.au/Articles/N_R/Remote-WA-free-meningococcal-vaccine).**
- **2018.**

**Stage 1 of the targeted program: summary of MenACWY vaccine doses administered and estimated vaccination coverage (%), data extracted on 18.12.2017**

	Goldfields		Kimberley		Pilbara		Total	
	2-11 months	12 months and over	2-11 months	12 months and over	2-11 months	12 months and over	2-11 months	12 months and over
Vaccine doses administered before 16.10.2017 <sup>1</sup>	0	82	0	71	0	27	1	180
Vaccine doses administered, 23.10.2017 onwards	25	1,713	26	819	7	582	58	3,115
Total vaccine doses administered to date	1,820		916		616		3,352	
Total population <sup>2</sup>	1,769		1011		714		3,494	
Estimated coverage*	103%		91%		86%		96%	

\* May be >100% because >1 dose is required for children <12months of age

**Stage 2 of the targeted program - Summary of MenACWY vaccine doses administered and estimated vaccination coverage (%), data extracted on 16.01.2018**

	Goldfields		Midwest		Total	
	2-11 months	12 months and over	2-11 months	12 months and over	2-11 months	12 months and over
Vaccine doses administered before 27.11.2017 <sup>1</sup>	638		33		671	
Vaccine doses administered, 27.11.2017 onwards	80	1,098	19	317	99	1,415
Total vaccine doses administered to date	1816		369		2,185	
Total population to be vaccinated	3,247		437		3,684	
Estimated coverage	56%		84%		59%	


NB: Total population to be vaccinated for expansion of program is: 2 months to 19 years Aboriginal residents and 2months to 19 years non Aboriginal residents if non Aboriginal people make up less than 50% of total population of the community/town.


1. The majority of these figures represent those who have received vaccine as part of the state-wide MenACWY vaccination program for 15-19 year olds that commenced in April 2017.

2. Australian Bureau of Statistics (ABS) 2016 census.

Please note: Regional population estimates are based on 2016 census, however, populations will vary due to significant movement of people. Vaccination coverage should consider local population estimates at time of vaccination.

# Weekly and cumulative total of number of Men ACWY vaccine doses administered, by region and week





### Further communiques

- The next communique will be issued on **26.01.2018**.

**WebEOC Incident Name:** 20171012 Targeted Regional WA MenW Outbreak Response

**Communique prepared by:** Donna Mak

T: +61 8 9388 4801 (0800-1700) | F: +61 8 9388 4801 | E: [pheoc@health.wa.gov.au](mailto:pheoc@health.wa.gov.au) | I: [www.health.wa.gov.au](http://www.health.wa.gov.au)

The contents of this e-mail transmission are intended solely for the named recipient(s), may be confidential, and may be privileged or otherwise protected from disclosure in the public interest. The use, reproduction, disclosure or distribution of the contents of this e-mail transmission by any person other than the named recipient(s) is prohibited. If you are not a named recipient please notify the sender immediately.